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Abstract
Neovascularization is an integral process of inflammatory reactions and subsequent repair cascades in tissue injury.
Monocytes/macrophages play a key role in the inflammatory process including angiogenesis as well as the defence mechanisms by
exerting microbicidal and immunomodulatory activity. Current studies have demonstrated that recruited monocytes/macrophages aid in
regulating angiogenesis in ischemic tissue, tumours and chronic inflammation. In terms of neovascularization followed by tissue regen-
eration, monocytes/macrophages should be highly attractive for cell-based therapy compared to any other stem cells due to their con-
siderable advantages: non-oncogenic, non-teratogenic, multiple secretary functions including pro-angiogenic and growth factors,
straightforward cell harvesting procedure and non-existent ethical controversy. In addition to adult origins such as bone marrow or
peripheral blood, umbilical cord blood (UCB) can be a potential source for autologous or allogeneic monocytes/macrophages. Especially,
UCB monocytes should be considered as the first candidate owing to their feasibility, low immune rejection and multiple characteristic
advantages such as their anti-inflammatory properties by virtue of their unique immune and inflammatory immaturity, and their pro-
angiogenic ability. In this review, we present general characteristics and potential of monocytes/macrophages for cell-based therapy,
especially focusing on neovascularization and UCB-derived monocytes.
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Cellular Medicine
Introduction
Monocytes, which are derived from monoblasts, haematopoietic
stem cell precursors in the bone marrow (BM), circulate in the
bloodstream before extravasating into tissues of the body. In the
tissues, monocytes differentiate into various types of tissue resi-
dent macrophages depending on their anatomical locations, for
example Langerhans cells in skin, Kupffer cells in liver, osteoclasts
in bone, microglia in central nervous system, alveolar
macrophages in lung and synovial type A cells in synovial joint
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[1–5] (Fig. 1). Monocytes/macrophages can perform phagocyto-
sis by using mediators such as antibodies or complement compo-
nents that coat the microbes or by binding to the pathogens
directly via specific receptors that recognize them (endocytosis).
Additionally, monocytes/macrophages are able to kill infected host
cells, through an immune system response, termed antibody-
mediated cellular cytotoxicity [4, 6]. Moreover, they are unique
immunoregulatory cells able to both stimulate and suppress
immune activities, including antigen presentation to T cells and
controlled secretion of a wide range of cytokines and growth fac-
tors [1, 3, 7]. The bottom line in monocyte/macrophage function
is that they play a major role in the inborn defence system by way
of killing pathogens through phagocytosis and cellular cytotoxic-
ity, and immunomodulation [1, 7].
Role of monocytes in neovascularization
Like neutrophils, one interesting function of monocytes/
macrophages is to promote angiogenesis related to inflammatory
reactions [8–10]. Angiogenesis (or neovascularization) is a major
element of inflammatory processes including subsequent repair
cascades [4]. During the early inflammatory process, circulating
blood monocytes extravasate into tissues [1]. Initially, neighbour-
ing endothelial and inflammatory cells regulate this monocyte pas-
sage through vessel walls by releasing of a series of adhesion and
chemotactic materials [1, 2, 11]. Along chemotactic and oxygen
gradients between normal and injured tissues, extravasated
monocytes move and gather into hypoxic and/or necrotic cores of
diseased tissues before differentiation into tissue macrophages.
The representative pathological tissues to which monocytes/
macrophages are apt to accumulate are as follows: solid tumours,
myocardial or cerebral infarction, synovial joints of chronic arthri-
tis or atheromatous plaques, bacterial infection and healing
wounds [1, 3, 11, 12] (Fig. 1).
After differentiation from monocytes, macrophages in tissue
have been known to exist as polarized populations, M1 and M2
subsets [12–14]. Whereas M1 polarized macrophages are power-
ful inflammatory cells that produce pro-inflammatory cytokines
and phagocytize pathogens, M2 macrophages modulate the
inflammatory responses and help with angiogenesis and tissue
repair [12–14]. Interestingly, in gene expression of macrophages,
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 1 Schematic diagram depicting monocyte/macrophage ontogeny. The pluripotent stem cells differentiate into myeloid or lymphoid progenitors in
BM. The granulocyte–monocyte progenitors are derived from the common myeloid progenitor cell before differentiating into myeloblast and monoblast.
Monocytes are differentiated from monoblast and subsequently move from the BM into the blood. Blood monocytes differentiate into various types of
resident macrophages depending on their anatomical locations after extravasating into tissues. On the other hand, during the early inflammatory
process, recruitment and transendothelial migration of circulating monocytes is augmented by a series of adhesion and chemotactic materials,
expressed by inflammatory cells. Recruited monocytes migrate along chemotactic and oxygen gradients between normal and injured tissues, and accu-
mulate within inflammatory and hypoxic cores in ischemia, or solid tumours, or chronic inflammatory diseases before differentiation into recruited
macrophages which have polarization, M1 or M2 subset.
J. Cell. Mol. Med. Vol 14, No 3, 2010
555
a combination of M1 and M2 subsets early in wound healing turns
into dominantly M2 genes later [15]. During the early stage of the
wound healing process, M1 macrophages lead to direct inflamma-
tory reaction that cleans up the wound and debris of microbes
and/or injured host tissues while tissue repair and angiogenesis
are initiated by M2 macrophages at the same time. In the late
stage when the cleansing by M1 macrophages is almost over, the
prevailing M2 macrophages go on with their work, tissue regener-
ation including angiogenesis [15]. Accumulating evidence sug-
gests that recruited monocytes/macrophages aid in modulating
and regulating neovascularization in ischemic tissue, tumours and
chronic inflammation such as arthritic joints and atherosclerosis.
Angiogenesis in ischemia
In recent years, the importance of circulating monocytes/
macrophages in neovascularization has been demonstrated in
ischemic diseases [16–18]. Arteriogenesis, the structural growth
of pre-established arteriolar webs into true effective collateral
arteries, seems to be initiated by increased fluid shear stress
which results from arterial obstruction within the developing 
collateral arteries and not induced by tissue hypoxia and ischemia
[19, 20]. In contrast, angiogenesis, the formation of new capillar-
ies from pre-existing blood vessels, is induced by hypoxia, and
capillary density increases in sites of severe and acute ischemia
[19, 21].
Although arteriogenesis and angiogenesis both induce neovascu-
larization through different mechanisms, monocytes/macrophages
essentially contribute to both actions. In arteriogenesis, abrupt arte-
rial flow obstruction resulting from an embolus or a progressive
stenosis increases fluid shear stress in the arteriolar web, and 
subsequently adhesion molecules and chemokines such as endothe-
lial adhesion molecule [22] and monocyte chemotactic protein-1
(MCP-1) [23] increase significantly. Blood monocytes are activated
and are drawn to the collateral artery by MCP-1. Once there, they go
through the vessel wall by way of binding to adhesion molecules
and/or differentiate into tissue macrophages before producing plenty
of growth factors and cytokines [4], which can promote endothelial
and smooth muscle cell proliferation [16, 20].
Angiogenesis is a combination of more intricate processes,
many of which are regulated by vascular endothelial growth factor
(VEGF) and its receptors (VEGFR), which are known to initiate
angiogenesis [16]. Recent data suggest, some subsets of
angiopoietins (Ang-1 and 2) and their receptors (Tie) are critical to
the secondary stages of the angiogenic process such as matura-
tion, stabilization and remodelling of vessels [24]. Hypoxia and tis-
sue necrosis significantly affect production of VEGF/VEGFR and
angiopoietin/Tie receptors [25–28]. In turn, VEGF and angiopoi-
etin induce the recruitment of endothelial progenitor cells and
monocytes/macrophages [28, 29].
Recruited monocytes/macrophages promote angiogenesis by
several potential mechanisms in each phase of the angiogenic
process. First, macrophages degrade the extracellular matrix
using matrix metalloproteinases (MMPs) (e.g. MMP-9) and prote-
olytic enzymes, leading to endothelial cell migration [30, 31]. Via
a path through the extracellular matrix, growth factors and
endothelial cells are mobilized from established vessels to form
new capillaries [16].
Second, monocytes/macrophages release many pro-angio-
genic cytokines such as interleukin (IL)-1, basic fibroblast
growth factor (bFGF), VEGF, IL-8, substance P, tumour necrosis
factor (TNF)-, transforming growth factor (TGF)- and - and
prostaglandins [4, 30, 31], which act directly or indirectly on pro-
moting endothelial cell proliferation, migration or tube formation
[4, 16, 31]. Although monocytes/macrophages are also able to
release angiostatic factors such as IL-12, IL-18 [31], throm-
bospodin 1, interferon- and - [4], their production of inhibitory
cytokines is regulated by pro-angiogenic factors. For example, 
IL-12 production is inhibited by increasing Ang-2 levels [28].
Third, monocytes/macrophages may differentiate into
endothelial cells, which help directly in vessel wall production 
[30, 32, 33]. With specific pro-angiogenic factor stimulation,
monocytes/macrophage progenitors can transdifferentiate into
endothelial-like cells, which are directly incorporated into new
blood vessels [16, 34–36].
Fourth, with exposure to VEGF or hypoxia, endothelial cells
produce MCP-1 [37, 38] as well as VEGF [30] and angiopoietin
[28], all of which activate and attract monocytes/macrophages
[16]. In reverse, monocytes/macrophages not only up-regulate
Tie-2 (angiopoietin receptor) [28], but also secrete MCP-1 and
VEGF when they are activated by hypoxia, which in turn influences
endothelial cell migration and proliferation [31], and even them-
selves by auto- and paracrine actions, and subsequently brings
redoubling effect to the angiogenesis process [39].
Angiogenesis in tumours and chronic inflammation
For recent decades, there has been accumulating evidence that
together with tumour cells themselves, monocytes/macrophages
also play a major role in angiogenesis and progression of tumours
[4] as neoplastic tissues exhibited neovascularization only with
macrophages [40] and monocyte depleted animals showed a sig-
nificant decrease in tumour angiogenesis [41]. The number of
macrophages in tumour tissue is greater than in most normal tis-
sues [42]. Augmented mobilization and differentiation from circu-
lating monocytes more likely result in increased macrophages in
tumour tissue, rather than simple proliferation of tissue
macrophages [12, 43]. The pro-inflammatory cytokines which are
induced by tumour cells and central hypoxia, attract mono-
cytes/macrophages to sites of neoplastic necrosis and growth [44,
45].
Most of all, monocytes/macrophages appear to be recruited to
promote neovascularization that is critical to tumour growth and
progression. In most tumours, significantly more of the tumour-
associated macrophages (TAMs) are of the M2 macrophage sub-
population, which potentiate angiogenesis, compared to the M1
subset which kills tumour cells [12, 14, 46]. M2 TAMs secrete
plenty of pro-angiogenic factors, such as VEGF, TNF-, IL-8, TGF-
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and bFGF [3, 12–14, 31, 43, 47], and a broad range of proteolytic
enzymes [47], which can break down the extracellular matrix and
in turn, lead to endothelial cell migration for angiogenesis [30, 31,
43]. Of importance, significant correlations between TAM and vas-
cular densities, have been observed in colon cancer [48], breast
cancer [49] and pancreatic cancer [50], which suggest that TAMs
potentiate tumour angiogenesis [43]. Besides, strong TAM recruit-
ment is significantly related to poor prognosis in some tumour
types [48, 49].
Angiogenesis also contributes to chronic inflammatory pathol-
ogy. The chronic inflammatory status is maintained by virtue of
new vessel formation, which continuously delivers inflammatory
cells and supplies oxygen and nutrients to the area of inflamma-
tion [51]. Mechanisms and characteristics of neovascularization
related to chronic inflammation are no different than angiogenesis
induced by ischemia or tumour. Most cytokines and growth fac-
tors known to regulate angiogenesis can be produced by mono-
cytes/macrophages [4]. During pannus formation in rheumatoid
arthritis and atheromatous plaque formation in atherosclerosis,
the proliferating inflamed tissue contains a number of inflamma-
tory cells, especially monocytes/macrophages, newly forming
vessels and derived inflammatory mediators [51]. The end result
is that increased monocytes/macrophages can be observed at
most inflammatory areas where angiogenesis is occurring in an
abnormal environment, including pathological conditions such 
as ischemia, tumour and chronic inflammatory disease as well as
wound healing [4, 51–53].
Monocytes versus stem cells 
for transplantation
A number of studies have been performed to explore the therapeu-
tic potential of monocytes/macrophages for arteriogenesis and/or
angiogenesis primarily in ischemic disease models [17, 54–57].
For arteriogenesis and angiogenesis, monocyte may be novel and
fascinating as a target cell for cell-based therapy towards promo-
tion of collateral vessel growth followed by tissue regeneration,
which can attenuate local tissue ischemia and improve clinical
outcome [58, 59]. Neovascularization from endogenous mono-
cytes can be induced directly by either an infusion of MCP-1 [56]
or granulocyte-macrophage colony stimulating factor (GM-CSF)
[54], or indirectly through a rebound effect after administration of
5-fluorouracil [55]; all of these materials can promote homing to
and accumulation around collateral arteries, or proliferation of
endogenous monocytes.
In addition, neovascularization can be achieved by the trans-
plantation of exogenous autologous or allogeneic monocytes with
or without ex vivo engineering. By developing an effective method
for isolation of monocytes from peripheral blood [60–63], an ade-
quate autologous monocyte stock can be collected. Although
peripheral blood yields a finite number of monocyte, an adequate
monocyte stock can be accumulated for future usage through
repeated harvesting of autologous monocytes from the patient’s
peripheral blood by leucapharesis [60]. The advance of ex vivo tis-
sue engineering leads to new strategies using monocytes as vehi-
cles for therapeutic gene transfection, for example delivery of GM-
CSF to promote neovascularization [17] as well as direct effectors
for cell transplantation. This technical development from cell iso-
lation to application should make monocytes more promising for
regenerative medicine, especially in terms of augmentation of
arteriogenesis and angiogenesis.
There may be several advantages of monocyte transplantation
(Table 1) compared to stem cells. First, unlike progenitor/stem cells,
they do not have the ability to self-renew and proliferate, thus
decreasing the potential for tumorogenesis from the cell transplant.
Second, they cannot differentiate into other cell lineages, which
could exert undesired effects in specific tissues if they are trans-
planted into or migrate into them. Third, unlike embryonic and foetal
tissues, they are free from ethical and moral issues for procurement
and transplantation because they can be easily collected from peri-
natal cord blood and adult peripheral blood or BM. Fourth, mono-
cyte transplantation can avoid an immune reaction such as graft-
versus-host disease (GvHD), which often happens after allogenic
leucocyte transfusion or BM transplantation in human leucocyte
antigen (HLA) mis-matched host. GvHD is an immune reaction
which results from activation of T cells in the graft (donor cells) after
detecting host tissues (recipient cells) as antigenically different [64].
The activated donor T cells produce an abundance of cytotoxic and
inflammatory cytokines and attack the host tissues. With respect to
GvHD, regardless of HLA matching, transplantation of a monocyte
fraction alone should be safe to a greater degree than that of
mononuclear fraction of BM or GM-CSF mobilized peripheral blood,
which is sure to include lymphocytes. Finally, monocytes/
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Advantages Disadvantages
No self-renewal No cell replacement effect
No self-proliferation
Possibility to augment deleterious
inflammatory reaction
No transdifferentiation
Possibility to promote tumour
angiogenesis
No tumour induction
Additional isolation and expansion
processes
No ethical and moral problem
Relative narrow applicable disorder
criteria such as ischemic disease
Possible repeated autologous 
harvesting 
Secretory function of several
cytokines and growth factors
Possible tissue engineering as a
vector for gene transfection
Table 1 Advantages versus disadvantages of monocytes/macrophages
for cell transplantation
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macrophages can secrete a number of cytokines, growth factors
and trophic materials which may directly promote other tissue
regeneration as well as angiogenesis [4]. For instance, VEGF has
been known to be able to stimulate neurogenesis [65, 66].
Recently there has been accumulating evidence suggesting
that monocytes can be a target cell for induced pluripotent stem
(iPS) cell technology. This hypothesis is based on the fact that the
monocyte itself is the progenitor of macrophages, dendritic cells,
synovial cells, microglia, etc. Of particular interest are program-
mable cells of human monocyte origin (PCMO) with multipotent
properties. PCMO which are dedifferentiated from CD14 periph-
eral blood monocytes by a combination of M-CSF and IL-3 in a 
6-day culture are responsive to inductive stimuli and consequently
can re-transdifferentiate into hepatocyte-like cells [67, 68], pan-
creatic islet-like cells [67] and chondrocytes [69]. These transdif-
ferentiated cells have shown a close resemblance to the original
cells morphologically, serologically and functionally in vitro and 
in vivo [67–69]. Transplanted human monocyte-derived hepato-
cytes secreted albumin in severe combined immunodeficiency
disease/non-obese diabetic mice [67]. Also, implanted islet-like
cells released insulin according to glucose levels and normalized
blood glucose in a diabetic mouse model [67]. Additionally, the
chondrocytes derived from PCMO appeared to produce type II col-
lagen based on messenger RNA expression [69]. Furthermore,
transplantation of PCMO themselves improved impaired heart
function from myocardial infarction (MI) in a mouse MI model
[70]. In this study, the authors revealed that implanted PCMO
induced angiogenesis in the infarction area, and PCMO from
infracted donor expressed higher VEGF than PCMO from healthy
donors and non-modulated monocytes. These findings suggest
that PCMO may transdifferentiate into other phenotypes as well as
hepatocytes and islet cells, including skin and neural cells. Thus,
monocytes may be used as an autologous source of pluripotent
stem cells for cell-based therapy, so-called patient specific iPS
cells, in a variety of intractable diseases beyond ischemia, such as
neurodegenerative disorders, diabetes, hepatic disease, etc.
However, like other cell-based therapies, clinical trials with
monocytes for intractable ischemic diseases still need more care-
ful pre-clinical investigations with regard to the issues of effective-
ness or safety. Some studies have failed to show a significant
effect of cell therapies with monocytes [71] or mononuclear cells
[72–74] from BM in the ischemic heart disease animal models or
real patients with MI. The mode of administration is also contro-
versial. It is reasonable to expect that the cells could be even more
effective if they were administered directly to the site of injury.
Therefore, intramyocardial [71–73] or intracoronary [74] delivery
of BM monocytes [71] or mononuclear cells [72–74] has been
popular in the research field of ischemic heart disease. By con-
trast, more feasible routes such as intravenous injection might be
considered because many adhesion molecules and chemoattrac-
tants are expressed at ischemic sites [22, 23] which could easily
recruit intravenously administered monocytes into the damaged
area. Moreover, we have demonstrated that intravenous injection
of mononuclear human umbilical cord blood (hUCB) cells was at
least similarly effective to intralesional implantation in short-term
follow-up of neurological function and more effective than direct
striatal implantation in producing long-term functional benefits to
the stroke animal [75]. Recently, intraperitoneal injection of hUCB
mononuclear cells has also shown a good effect in a neonatal rat
model of hypoxic-ischemic brain damage [76]. Finally, the specific
role and function of monocytes/macrophages in inflammation and
immune modulation has still not been fully understood. Their dele-
terious potential in tumour vascularization, diabetic retinopathy,
arthritic pannus and atherosclerotic plaque development still may
need serious investigation [60].
Monocytes from umbilical cord blood
Monocytes constitute ~5–10% of peripheral blood leucocytes in
human beings [77, 78], whereas these cells comprise 2% of BM
mononuclear cells [78]. By contrast, no difference in monocyte
content between UCB and adult peripheral blood has been
reported [79, 80]. Therefore, BM and UCB, as well as peripheral
blood can be potential candidates as a source of autologous or
allogeneic monocytes/macrophages. In fact, BM and UCB are the
current gold standard sources of haematopoietic progenitor cells
used to reconstitute blood lineages after myeloablative therapy
in malignant and non-malignant blood disease. However, the
potential of their stem cell population for cell-based therapy has
also been demonstrated in other degenerative disorders, espe-
cially ischemic disease. There is accumulating evidence that
delivery of BM- or UCB-derived stem or mononuclear cells to
areas of ischemia by direct local transplantation or injection into
blood, can improve the pathological lesion and functional
impairment in pre-clinical [81–87] and clinical studies [88–92].
This improvement has been thought to result in part from
paracrine effect with an increase in angiogenesis induced by
stem cells in the ischemic and/or peri-ischemic core [82, 85,
93–95] even though the mechanisms to exert their angiogenic
effects are not completely understood.
Recently, our group revealed that surgical intramyocardial mul-
tiple one-time injections of autologous BM mononuclear cells in
patients with refractory angina showed a progressive improve-
ment in angina classification as well as in reperfused myocardium
area during 18 month follow-up [96]. It is of interest that a posi-
tive correlation was noted between monocyte concentration in the
graft formulation and clinical improvement (Table 2). This sug-
gests that monocytes should play a major role in functional recov-
ery, probably through induction of myocardial angiogenesis.
Meanwhile, monocytes in UCB essentially are unique compared
to those originating in adult BM and peripheral blood [84]. Only
adult monocytes are activated by hepatocyte growth factor, which is
essential for normal monocyte functions such as antigen presenta-
tion [97]. The UCB monocytes express less HLA-DR than adult cells
so their cytotoxic capacity is lower [98]. Furthermore, UCB mono-
cytes do not differentiate into mature dendritic cells to the same
extent as mature monocytes even with stimulation by IL-4 and 
GM-CSF [99]; dendritic cells play a major role in activation of naïve
T cells. Secretory function is also different between UCB monocytes
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and adult blood monocytes. Less secretion of IL-1 and TNF-,
both of which stimulate inflammation as well as play a major role in
immune reactions such as GvHD [100], from UCB monocytes after
exposure to recombinant interferon- is most likely related to differ-
ences in the expression of monocytes antigens such as CD64,
CD14, CD33 and CD45RO with adult blood monocytes [64]. CD14
monocytes/macrophages in uterine decidual tissues and blood of
normal pregnant women are predominantly of the M2 subset, which
modulates maternal-foetal immune reaction and promotes tissue
remodelling and angiogenesis to maintain successful pregnancy
[101]. These findings suggest that most UCB monocytes may also
become M2 polarized macrophages which are less inflammatory
and more angiogenic because decidual macrophages probably are
differentiated from UCB monocytes in part.
The immaturity of immune and inflammation stimulatory func-
tion in UCB monocytes may contribute to a lower incidence of
immune rejection including GvHD and/or inhibition of deleterious
inflammatory reaction after transplantation even though they are
from an allogeneic source. Although, transplantation of monocytes
from autologous BM or peripheral blood can avoid immune rejec-
tion and GvHD, BM harvesting itself needs additional time, cost and
physical burden to the patients. Repeated monocyte harvesting and
isolation from the patient’s own peripheral blood also necessitates
extra time and cost. By contrast, in terms of target for cell-based
therapy, one of the largest advantages of UCB monocytes com-
pared to adult autologous monocytes is rapid availability. For
example, in stroke patients, ‘proper timing’ is critical and it may not
be feasible to recover, process and manipulate quality of monocyte
cells, under current good manufacturing practices conditions from
the patient within the therapeutic window. As far as feasibility and
safety is concerned, UCB monocytes are the most promising allo-
genic cells that can be manipulated completely in advance without
harm to donor or recipient before transplantation even if the cells
are immunologically mismatched to those of the recipient. Table 3
shows the advantages of UCB monocytes for cell-based therapy.
This superiority of UCB monocytes over BM and peripheral
blood should lead to more brisk exploration of their promising role
for cell-based therapy. Recently, our group showed that transplan-
tation of hUCB cells from which the monocyte subpopulation
(CD14) was depleted failed to improve neurological outcome to
the same extent as transplantation of the other UCB cells (T-cell
depleted, B-cell depleted, CD133 depleted and whole mononu-
clear fraction) in the middle cerebral artery occlusion rat model
[102]. Further, removal of the CD14 monocytes from UCB prepa-
ration resulted in a failure of the cells to reduce infarct size (Fig.
2). In regard to angiogenesis, these findings suggest that trans-
plantation of monocyte-depleted hUCB could not induce angio-
genesis properly, and in turn, could not rescue compromised cells
surrounding the infarct core or improve neurological function. At
least, the monocyte subpopulation of UCB should be critical to
UCB-induced recovery following stroke.
In addition, we also demonstrated that locomotor dysfunction
and memory were improved after intravenous transplantation of
monocyte/macrophages from hUCB in a Sanfilippo syndrome type B
(mucopolysaccharidosis type III B) mouse model [103]. In
Sanfilippo syndrome type B, a deficiency of the -N-acetylglu-
cosaminidase (Naglu) enzyme leads to accumulation of heparan
sulphate (HS), a glycosaminoglycan within cells and finally draws
to progressive cerebral and systemic organ abnormalities.
Although glycosaminoglycans are known as extracellular matrix
molecules that have influence on the phagocytic ability of
macrophages, the function of monocytes/ macrophages in a
pathological HS-rich condition such as Sanfilippo syndrome is
unclear. In this study, as well as neurological improvement,
histopathological study showed that the number of microglia
(macrophage in brain) increased in all hippocampal areas of
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Table 2 Spearman’s correlation coefficients (rs) between monocytes of
autologous BM mononuclear cells and improvement of angina symp-
toms for 18 months following transplantation into myocardium (from
Hossne et al. [96])
CCSAC Monocytes
3 months rs 0.759
P-value 0.048
6 months rs 0.759
P-value 0.048
12 months rs 0.759
P-value 0.048
18 months rs 0.759
P-value 0.048
CCSAC: Canadian Cardiovascular Society Angina Classification.
months: months of follow-up.
If P  0.05, there is a significant correlation between each subpopula-
tion and improvement of CCSAC.
Table 3 Advantages of UCB monocytes/macrophages compared to
adult origin for cell transplantation
Immature immunoregulatory function
Immature inflammatory reaction
Possible anti-inflammatory reaction
More polarization to M2 macrophage subset that promotes tissue
remodelling and angiogenesis
Low incidence of GvHD compared to adult origin BM and peripheral
blood
Relatively easy procurement compared to BM
No burden to donors
J. Cell. Mol. Med. Vol 14, No 3, 2010
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Naglu mutant mice treated with monocytes and HS levels were
reduced in the livers of treated mice. Furthermore, urinary disten-
sion, usually a significant problem in aged afflicted mice, was also
improved in treated mice. These findings suggest that administra-
tion of hUCB monocytes/macrophages benefit mice modelling
MPS III B, probably owing to the influence from transplanted cells
on mechanisms of phagocytosis in the HS-rich environment of
this disease [103].
Meanwhile, evidence is accumulating that suggests hUCB
mononuclear cells containing monocytes may be a good candi-
date for cell-based therapies for stroke and ischemic heart dis-
eases including acute MI. Of interest, recently Pimentel-Coelho 
et al. [76] demonstrated that intraperitoneal transplantation of
hUCB mononuclear cells, 3 hrs after the hypoxic-ischemic insult,
improved developmental sensorimotor reflexes, in the first week
after the injury in a neonatal rat model of hypoxic-ischemic brain
damage. They also observed a decrease in the number of dying
neurons in the striatum as well as a decline in the activated
microglia in the cerebral cortex of treated animals compared to the
control group. With respect to the field of cardiovascular diseases,
a number of studies revealed that intravenous [104] or intramy-
ocardial [105, 106] injection of hUCB mononuclear cells after
acute MI increased microvessels and decreased collagen deposi-
tion in the acute MI rodent models. The grafted human cells still
survived in the animals’ myocardium. Besides, at 4–6 weeks after
transplantation, improvement of left ventricular wall function was
observed [105, 106].
In contrast to their original role in inflammation, the use of UCB
monocytes may prevent probable harmful effects or exert anti-
inflammatory effects. There has been accumulating evidence that
UCB mononuclear cells provide anti-inflammatory effects in several
disease conditions. Previously, we demonstrated that the transplan-
tation of hUCB mononuclear cells significantly decreased the num-
ber of CD45/CD11b (microglia/macrophage) and CD45/B220
(B cell) cells in the brain of rats with middle cerebral artery occlu-
sion [107]. In addition, UCB transplantation decreased the pro-
inflammatory cytokines such as TNF- and IL-1 [107]. Recently,
we also revealed that transplantation of hUCB mononuclear cells via
intravenous injection in older rats can significantly reduce the num-
ber of activated microglia, and increase neurogenesis [108].
Chronic microgliosis reflects chronic inflammatory reactions in
brain tissue, and is involved in structural damage to neurons in
ischemic injury as well as in other neurodegenerative diseases such
as Parkinson’s and Alzheimer’s disease [109]. Therefore, this find-
ing suggests that UCB mononuclear cells can ameliorate the hostile
environment of the aged hippocampus by way of an anti-inflamma-
tory reaction, and subsequently regenerate potential of the aged
neural stem/progenitor cells. On the basis of above studies, a mono-
cyte fraction which comprises a considerable proportion of UCB
mononuclear cells, could have the potential, anti-inflammatory
effects which may be partially responsible for the functional
improvements seen in animal models of injury, including stroke.
Conclusions
Monocytes/macrophages may provide a promising alternative to
stem cell transplantation for therapeutic purposes with the ability
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Neuroprotection of striatal and cortical degeneration after middle
cerebral artery occlusion in a rat model of stroke is attenuated by removal
of monocytes. There is extensive neurodegeneration in striatum and cor-
tex after middle cerebral artery occlusion as determined with FluoroJade
staining (top panel). Administering human UCB cells minimizes this dam-
age (bottom panel) whereas removal of the CD14 monocytes from the
human UCB eliminates this neuroprotective effect. Scale bar  2.0 mm.
(From Womble et al. [102].)
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to promote arteriogenesis and angiogenesis in varied ischemic
diseases. Potential hazardous side effects from transplantation
with monocytes/macrophages can be prevented by careful 
evaluation to check whether the proposed recipient has a pre-
existing malignancy, uncontrolled diabetes, arthritis, atheroscle-
rosis or not. If during pre-treatment evaluation, it is confirmed
that the patients have a pre-existing disease which may be exac-
erbated by monocyte transplantation, they would be excluded
before cell transplantation. This is unlikely because to the best of
our knowledge, monocyte-related complications such as pre-
existing tumour or chronic inflammatory disease progression,
have not been reported after BM or UCB transplantation in
patients with haematological malignant or non-malignant dis-
eases even though monocytes comprise a considerable portion
of BM and UCB. These UCB monocytes should be the first 
candidate out of several due to their outstanding feasibility,
safety and multiple functions such as anti-inflammatory reaction
as well as angiogenesis.
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